Altium Capital Management LP Avadel Pharmaceuticals PLC Transaction History

Altium Capital Management LP

  • $283 Million
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024
BUY
$12.55 - $17.22 $6.94 Million - $9.52 Million
553,057 New
553,057 $9.34 Million
Q1 2023

May 15, 2023
BUY
$6.41 - $9.95 $3.21 Million - $4.98 Million
500,000 New
500,000 $4.58 Million
Q1 2022

May 16, 2022
SELL
$5.46 - $8.29 $2.41 Million - $3.65 Million
-440,589 Closed
0 $0
Q1 2021

May 06, 2021
SELL
$6.61 - $10.07 $165,250 - $251,750
-25,000 Reduced 5.37%
440,589 $3.98 Million
Q4 2020

Feb 16, 2021
BUY
$5.03 - $7.95 $2.34 Million - $3.7 Million
465,589 New
465,589 $3.11 Million

Others Institutions Holding AVDL

# of Institutions
8
Shares Held
1.07M
Call Options Held
0
Put Options Held
0
View Full List

About AVADEL PHARMACEUTICALS PLC

AVDL Quotes by TradingView
  • Ticker AVDL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 60,581,300
  • Market Cap $650M
  • Description
  • Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...
More about AVDL
Track This Portfolio

Track Altium Capital Management LP Portfolio

Follow Altium Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Altium Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Altium Capital Management LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email